Retatrutide's triple-agonist mechanism (GLP-1 + GIP + glucagon) produces diarrhea in approximately 34% of users at 12 mg, compared to roughly 30% for semaglutide at 2.4 mg
The grey market reality The gap between demand for healing peptides and regulated supply has created a significant grey market
However, subcutaneous injection is the standard route for systemic and musculoskeletal effects, as it provides more reliable bioavailability and allows injection near the injury site
Human Safety Data Is Minimal A tiny 2025 pilot study testing IV BPC-157 up to 20 mg in 2 healthy adults found it well tolerated with no adverse events and no biomarker changes, but 2 subjects provide essentially zero statistical power
Earlier vaccinations or infections have continued to help prevent severe disease and death but protection wanes over time, especially against milder infections as the virus continually evolves
The comparison is understandable, especially for patients who have been dealing with lingering pain, slow recovery, old injuries, or frustration after standard therapies